Spesolimab,
does it really help with Week-1 pustular clearance in an acute generalized pustular psoriasis flare?
research showsGrade C. Week-1 GPPGA pustulation score zero occurred in 19/35 (54%) versus 1/18 (6%), an absolute difference of 48 points (P<0.001). This was a 53-person surrogate-outcome trial.
ads claimRapid pustular clearance should not be converted into long-term relapse or survival benefit.
Useful facts when choosing a product
- IL-36 receptor antibody.
- Effisayil 1 enrolled 53 people.
- Infection monitoring matters.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.spesolimab.UNK.week-1-pustular-clearance-in-an-acute-generalized-pustular-psoriasis-flare.treat.placeboUnknown > Spesolimab > Unknown > Week-1 pustular clearance in an acute generalized pustular psoriasis flare > Treatment or remission claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Four gates: ① Defects: none; the candidates reviewed were fewer than 200 participants and under 12 weeks. ② The n=53 sample and week-1 endpoint formally match those listed items. ③ The paper randomized 53 patients, 35/18, and measured the primary endpoint "at the end of week 1." ④ Large recruitment is realistically impossible in this rare disease, and the question was rapid control of an acute flare; placebo patients crossed to open-label spesolimab after week 1, making a longer placebo comparison impossible. Both are unavoidable and therefore not counted, giving B0 with no defects.
Why this is classified as C (54)
A 48-point difference is large, but a surrogate endpoint and one manufacturer trial give C, 54. The n=53 sample and week-1 comparison are disclosed but not counted as axis-6 defects because they were unavoidable.
Counterpoint. Rarity explains but does not remove imprecision.
Rejudgment record. Axes and scorer agree — Effisayil 1 week-1 pustular clearance
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Week-1 pustular clearance | C | Rates were 54% versus 6%. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Bachelez H et al. 2021 Effisayil 1 | Phase 2 double-blind placebo-controlled randomized trial | 53 participants (35/18) | Funded by Boehringer Ingelheim | GPPGA pustulation subscore zero at week 1 | 19/35 (54%) vs 1/18 (6%); absolute difference 48 points; P<0.001 | Pivotal surrogate evidence |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Evidence date: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of Spesolimab for 1-Week Pustular Clearance in Generalized Pustular Psoriasis Flares, a Surrogate Outcome — Evidence Grade C·54. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/spesolimab-gpp-week1-pustular-clearance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.